[October 23, 2014]

MedLumics Introduces NITID Skin Imaging System at EADV

MedLumics, a medical imaging company specializing in advanced optical coherence tomography (OCT) technology, debuted its NITID^TM skin imaging system at the 23^rd Annual European Academy of Dermatology and Venereology Congress in Amsterdam. NITID is a handheld diagnostic device designed to help dermatologists quickly and minimally invasively diagnose skin cancer. Once approved by regulatory bodies, it will be the first point-of-care OCT imaging device that can produce dynamic, real-time, high-resolution diagnostic images with tissue penetration capability of up to two millimeters.

"NITID is the result of a decade of research in optical miniaturization technology, and we are thrilled to introduce it at EADV," said Eduardo Margallo, CEO of MedLumic. "NITID integrates three imaging modalities in one easy-to-use probe, thereby enabling physicians to produce high-quality images of a patient's skin and determine whether skin cancer is present without an invasive biopsy. We believe NITID is a gateway into the future of personalized dermatology, supporting the introduction of new non-surgical treatments, and could not be more pleased with the positive reception and validation it received at EADV."

The NITID device combines epiluminescence microscopy and OCT imagery in a patent-protected, built-in display that integrates seamlessly with current patient-centered workflows. By means of infrared light, this diagnostic image modality is able to obtain, in a non-invasive way, sectional images with micrometric resolution from the inside of biological tissues. It is designed to provide a complete solution to patient and image management, supporting lesion mapping and follow-up, and will be completely portable, allowing physicians to use throughout their offices. NITID will bring clinical value across several dermatology and skin care indications.

Non-melanoma skin cancer is the most common form of skin cancer in Caucasian populations, costing more than $11 billion to treat annually in the United States. Melanoma is the fifth most common and deadly tumor type; approximately 2 percent of American men and women will suffer from it at some point during their lifetime. However, there is currently no compact, cost-efficient and non-invasive way to diagnose malignant tissue.

About MedLumics

Founded in 2009, MedLumics is a medical imaging company specializing in advanced optical coherence tomography (OCT) devices. Its proprietary integrated optics platform technology combines optical and electrical components in a miniature package, enabling for the first time ultra-portable, hand-held OCT systems that produce high quality real-time images. The systems allow physicians to improve diagnostic and therapeutic procedures through a non-invasive optical evaluation of tissue. MedLumics received a 3.5 million Euro/4.7 million USD Series A financing from joint investors Ysios Capital Partners and "la Caixa" (through Caixa Capital Risc) in November 2011. For more information, visit www.medlumics.com.

[ Back To TMCnet.com's Homepage ]